Myeloma Today: Spring 2020

Dear Reader

  • A message from IMF President Susie Novis

Scientific & Clinical

  • Immunotherapy in Myeloma: Attacking the Plasma Cell in New Ways
  • The FDA Approves Isatuximab-irfc (Sarclisa®) for Relapsed Refractory Myeloma

Special Event

  • Myeloma Action Month

Advocacy

  • Diversity within clinical trials

Myeloma Warriors

  • Magical Miles for Myeloma

 

click on the rectangle icon to view the publication fullscreen


with support from:
Amgen, Bristol-Myers Squibb, Genentech, and Takeda Oncology

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.